Physician profile
Jack Azad
NPI 1841489440
$34,536.79
in general payments reported to CMS, 2019-2025
60 companies · $5,614 in 2025
The $5,614 reported for 2025 was more than what 99% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,329 · 2020: $4,219 · 2021: $6,528 · 2022: $6,217 · 2023: $4,936 · 2024: $3,693 · 2025: $5,614.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Education: $17.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,225.22 |
| Education | $17.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $4,823.93 | 2019-2024 | Xarelto, Invega Sustenna, Invega Trinza |
| Amgen INC. | $3,339.24 | 2019-2025 | Repatha, Otezla, Evenity |
| Abbvie INC. | $2,858.19 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals LP | $2,855.52 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Alkermes, INC. | $2,692.91 | 2022-2025 | Aristada, Lybalvi, Aristada Initio |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $2,590.08 | 2020-2025 | Caplyta |
| Pfizer INC. | $2,388.68 | 2019-2025 | |
| Biohaven Pharmaceuticals, INC. | $1,480.60 | 2021 | |
| Glaxosmithkline, LLC. | $1,124.83 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $739.06 | 2019-2025 | Mounjaro, Zepbound, Emgality |
| Novo Nordisk INC | $711.04 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Allergan, INC. | $644.04 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $593.84 | 2019-2023 | |
| Ardelyx, INC. | $527.80 | 2023-2025 | Ibsrela |
| Gilead Sciences, INC. | $523.36 | 2019-2025 | Biktarvy |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Azad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.